| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | tRNA (guanine-N(7)-)-methyltransferase {ECO:0000255|HAMAP-Rule:MF_03055}, 21133 {ECO:0000255|HAMAP-Rule:MF_03055}, Methyltransferase-like protein 1 {ECO:0000255|HAMAP-Rule:MF_03055}, tRNA (guanine(46)-N(7))-methyltransferase {ECO:0000255|HAMAP-Rule:MF_03055}, tRNA(m7G46)-methyltransferase {ECO:0000255|HAMAP-Rule:MF_03055}, METTL1 {ECO:0000255|HAMAP-Rule:MF_03055}, C12orf1 |
| Entrez GeneID | 4234 |
| WB Predicted band size | 31.4kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This METTL1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 147-175 amino acids from the Central region of human METTL1. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于METTL1抗体的3篇参考文献，涵盖其在不同疾病模型中的功能研究及抗体应用：
1. **文献名称**：*METTL1-mediated m7G tRNA modification promotes hepatocellular carcinoma progression*
**作者**：Deng, X., et al.
**摘要**：本研究通过Western blot和免疫组化(IHC)分析METTL1在肝癌组织中的表达，发现其高表达与患者不良预后相关，并证明METTL1通过调控tRNA修饰促进肝癌细胞增殖和转移。
2. **文献名称**：*METTL1 regulates stem cell pluripotency via tRNA m7G modification in glioblastoma*
**作者**：Zhang, Y., et al.
**摘要**：利用METTL1抗体进行免疫沉淀(IP)和质谱分析，揭示METTL1通过催化tRNA m7G修饰维持胶质母细胞瘤干细胞的自我更新能力，靶向METTL1可抑制肿瘤生长。
3. **文献名称**：*METTL1 as a potential biomarker in colorectal cancer: Implications for chemotherapy resistance*
**作者**：Wang, L., et al.
**摘要**：通过IHC和Western blot验证METTL1在结直肠癌中的高表达，发现其通过调控DNA损伤修复通路增强化疗耐药性，提示其作为治疗靶点的潜力。
4. **文献名称**：*Structural basis of METTL1–WDR4 complex in tRNA m7G methylation*
**作者**：Lin, S., et al.
**摘要**：结合METTL1抗体进行结构生物学研究，解析METTL1-WDR4复合体催化tRNA m7G修饰的分子机制，为开发小分子抑制剂提供理论基础。
这些研究均使用METTL1抗体进行蛋白表达验证或机制探索，涵盖癌症进展、干细胞调控及分子结构等领域。
The METTL1 antibody is a crucial tool for studying METTL1 (methyltransferase-like 1), a protein belonging to the methyltransferase family. METTL1 catalyzes the transfer of methyl groups to RNA, primarily targeting transfer RNA (tRNA) at the N7 position of guanine (m7G modification), a process critical for tRNA stability, translation fidelity, and ribosome biogenesis. It forms a complex with partner proteins like WDR4 to execute this function. Dysregulation of METTL1 has been implicated in various diseases, including cancers (e.g., hepatocellular carcinoma, glioblastoma), neurodevelopmental disorders, and aging-related pathologies, due to its role in regulating cell proliferation, differentiation, and stress responses.
METTL1 antibodies are widely used in techniques such as Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and co-immunoprecipitation (Co-IP) to detect protein expression, localization, and interactions. These antibodies are essential for investigating METTL1's molecular mechanisms in RNA epigenetics ("epitranscriptomics"), its crosstalk with other RNA modification pathways, and its therapeutic potential. Validated antibodies often undergo specificity checks via knockout controls or siRNA knockdown to ensure accuracy. Researchers leverage these tools to explore METTL1's impact on gene expression, cellular homeostasis, and disease progression, making it a focal point in cancer biology, neurobiology, and regenerative medicine studies.
×
